Brief: Pooled Data From The Pivotal Phase 3 Vanish Program Published In The Journal Of Women’S Health

Scynexis

03/11/2022 12:45

Nov 3 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * POOLED DATA FROM THE PIVOTAL PHASE 3 VANISH PROGRAM
PUBLISHED IN
THE JOURNAL OF WOMEN’S HEALTH DEMONSTRATE SIGNIFICANT EFFICACY
OF IBREXAFUNGERP OVER PLACEBO FOR TREATMENT OF VAGINAL YEAST
INFECTION
    * SCYNEXIS INC - CLINICAL CURE RATES, IN POOLED ANALYSIS,
WERE
STATISTICALLY SIGNIFICANTLY GREATER FOR IBREXAFUNGERP WHEN
COMPARED WITH PLACEBO
    * SCYNEXIS INC - IN POOLED ANALYSIS, PATIENTS RECEIVING
IBREXAFUNGERP EXPERIENCED SIGNIFICANTLY HIGHER RATES OF CLINICAL
IMPROVEMENT
    * SCYNEXIS INC - IN POOLED ANALYSIS, PATIENTS RECEIVING
IBREXAFUNGERP EXPERIENCED , COMPLETE SYMPTOM RESOLUTION,
MYCOLOGICAL CURE COMPARED TO PLACEBO
    * SCYNEXIS INC - IBREXAFUNGERP DEMONSTRATED CONSISTENT
EFFICACY IN
IMPORTANT PATIENT SUB-POPULATIONS

Source text for Eikon:  ID:nGNX3yYVJf 
Further company coverage:  SCYX.O 
 ((Reuters.Briefs@thomsonreuters.com;))